A systematic review and meta-analysis of immune-mediated liver dysfunction in non-small cell lung cancer.
CONCLUSION: The application of ICIs could result in a higher incidence and relative risk of all grade immune-induced liver dysfunction. Moreover, immunotherapy combined with chemotherapy may also increase relative risk of all grade hepatic AEs when compared with monotherapy. Prompt recognition and proper administration is required for clinicians to prevent potentially hepatic deterioration.
PMID: 32371246 [PubMed - as supplied by publisher]
Source: International Immunopharmacology - Category: Allergy & Immunology Authors: Lin LL, Lin GF, Yang F, Chen XQ Tags: Int Immunopharmacol Source Type: research
More News: Allergy & Immunology | Cancer | Cancer & Oncology | Chemotherapy | Clinical Trials | Databases & Libraries | Hepatitis | Immunotherapy | Liver | Lung Cancer | Non-Small Cell Lung Cancer | Science | Study | Urology & Nephrology